Summary
According to APO Research, The global Psychoactive Substances market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Psychoactive Substances is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Psychoactive Substances is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Psychoactive Substances is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Psychoactive Substances is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Psychoactive Substances include Alpha-CAT, AusCann Group Holdings Pty Ltd., Cannabics Pharmaceuticals Inc., Cape Bouvard Technologies Pty Ltd, Cyrelian Pty Ltd., Enecta., GD Pharma, GW Pharmaceuticals PLC. and MedReleaf Australia, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Psychoactive Substances, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Psychoactive Substances, also provides the revenue of main regions and countries. Of the upcoming market potential for Psychoactive Substances, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Psychoactive Substances revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Psychoactive Substances market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Psychoactive Substances revenue, projected growth trends, production technology, application and end-user industry.
Psychoactive Substances Segment by Company
Alpha-CAT
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Cape Bouvard Technologies Pty Ltd
Cyrelian Pty Ltd.
Enecta.
GD Pharma
GW Pharmaceuticals PLC.
MedReleaf Australia
Teewinot Life Sciences
Tilray
Zynerba Pharmaceuticals
Psychoactive Substances Segment by Type
Cannabinoids
Hallucinogens
Stimulants
Depressants
Psychoactive Substances Segment by Application
Neuropathic Disorders
Spasticity
Cancer
Psychoactive Substances Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychoactive Substances market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Psychoactive Substances and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychoactive Substances.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Psychoactive Substances in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Psychoactive Substances company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psychoactive Substances revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
- Market Overview
- Product Definition
- Psychoactive Substances Market by Type
- Global Psychoactive Substances Market Size by Type, 2020 VS 2024 VS 2031
- Cannabinoids
- Hallucinogens
- Stimulants
- Depressants
- Psychoactive Substances Market by Application
- Global Psychoactive Substances Market Size by Application, 2020 VS 2024 VS 2031
- Neuropathic Disorders
- Spasticity
- Cancer
- Assumptions and Limitations
- Study Goals and Objectives
- Psychoactive Substances Market Dynamics
- Psychoactive Substances Industry Trends
- Psychoactive Substances Industry Drivers
- Psychoactive Substances Industry Opportunities and Challenges
- Psychoactive Substances Industry Restraints
- Global Growth Perspective
- Global Psychoactive Substances Market Perspective (2020-2031)
- Global Psychoactive Substances Growth Trends by Region
- Global Psychoactive Substances Market Size by Region: 2020 VS 2024 VS 2031
- Global Psychoactive Substances Market Size by Region (2020-2025)
- Global Psychoactive Substances Market Size by Region (2026-2031)
- Competitive Landscape by Players
- Global Psychoactive Substances Revenue by Players
- Global Psychoactive Substances Revenue by Players (2020-2025)
- Global Psychoactive Substances Revenue Market Share by Players (2020-2025)
- Global Psychoactive Substances Players Revenue Share Top 10 and Top 5 in 2024
- Global Psychoactive Substances Key Players Ranking, 2023 VS 2024 VS 2025
- Global Psychoactive Substances Key Players Headquarters & Area Served
- Global Psychoactive Substances Players, Product Type & Application
- Global Psychoactive Substances Players Establishment Date
- Market Competitive Analysis
- Global Psychoactive Substances Market CR5 and HHI
- 2024 Psychoactive Substances Tier 1, Tier 2, and Tier 3
- Global Psychoactive Substances Revenue by Players
- Psychoactive Substances Market Size by Type
- Global Psychoactive Substances Revenue by Type (2020 VS 2024 VS 2031)
- Global Psychoactive Substances Revenue by Type (2020-2031)
- Global Psychoactive Substances Revenue Market Share by Type (2020-2031)
- Psychoactive Substances Market Size by Application
- Global Psychoactive Substances Revenue by Application (2020 VS 2024 VS 2031)
- Global Psychoactive Substances Revenue by Application (2020-2031)
- Global Psychoactive Substances Revenue Market Share by Application (2020-2031)
- Company Profiles
- Alpha-CAT
- Alpha-CAT Comapny Information
- Alpha-CAT Business Overview
- Alpha-CAT Psychoactive Substances Revenue and Gross Margin (2020-2025)
- Alpha-CAT Psychoactive Substances Product Portfolio
- Alpha-CAT Recent Developments
- AusCann Group Holdings Pty Ltd.
- AusCann Group Holdings Pty Ltd. Comapny Information
- AusCann Group Holdings Pty Ltd. Business Overview
- AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue and Gross Margin (2020-2025)
- AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio
- AusCann Group Holdings Pty Ltd. Recent Developments
- Cannabics Pharmaceuticals Inc.
- Cannabics Pharmaceuticals Inc. Comapny Information
- Cannabics Pharmaceuticals Inc. Business Overview
- Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue and Gross Margin (2020-2025)
- Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio
- Cannabics Pharmaceuticals Inc. Recent Developments
- Cape Bouvard Technologies Pty Ltd
- Cape Bouvard Technologies Pty Ltd Comapny Information
- Cape Bouvard Technologies Pty Ltd Business Overview
- Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue and Gross Margin (2020-2025)
- Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio
- Cape Bouvard Technologies Pty Ltd Recent Developments
- Cyrelian Pty Ltd.
- Cyrelian Pty Ltd. Comapny Information
- Cyrelian Pty Ltd. Business Overview
- Cyrelian Pty Ltd. Psychoactive Substances Revenue and Gross Margin (2020-2025)
- Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio
- Cyrelian Pty Ltd. Recent Developments
- Enecta.
- Enecta. Comapny Information
- Enecta. Business Overview
- Enecta. Psychoactive Substances Revenue and Gross Margin (2020-2025)
- Enecta. Psychoactive Substances Product Portfolio
- Enecta. Recent Developments
- GD Pharma
- GD Pharma Comapny Information
- GD Pharma Business Overview
- GD Pharma Psychoactive Substances Revenue and Gross Margin (2020-2025)
- GD Pharma Psychoactive Substances Product Portfolio
- GD Pharma Recent Developments
- GW Pharmaceuticals PLC.
- GW Pharmaceuticals PLC. Comapny Information
- GW Pharmaceuticals PLC. Business Overview
- GW Pharmaceuticals PLC. Psychoactive Substances Revenue and Gross Margin (2020-2025)
- GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio
- GW Pharmaceuticals PLC. Recent Developments
- MedReleaf Australia
- MedReleaf Australia Comapny Information
- MedReleaf Australia Business Overview
- MedReleaf Australia Psychoactive Substances Revenue and Gross Margin (2020-2025)
- MedReleaf Australia Psychoactive Substances Product Portfolio
- MedReleaf Australia Recent Developments
- Teewinot Life Sciences
- Teewinot Life Sciences Comapny Information
- Teewinot Life Sciences Business Overview
- Teewinot Life Sciences Psychoactive Substances Revenue and Gross Margin (2020-2025)
- Teewinot Life Sciences Psychoactive Substances Product Portfolio
- Teewinot Life Sciences Recent Developments
- Tilray
- Tilray Comapny Information
- Tilray Business Overview
- Tilray Psychoactive Substances Revenue and Gross Margin (2020-2025)
- Tilray Psychoactive Substances Product Portfolio
- Tilray Recent Developments
- Zynerba Pharmaceuticals
- Zynerba Pharmaceuticals Comapny Information
- Zynerba Pharmaceuticals Business Overview
- Zynerba Pharmaceuticals Psychoactive Substances Revenue and Gross Margin (2020-2025)
- Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio
- Zynerba Pharmaceuticals Recent Developments
- Alpha-CAT
- North America
- North America Psychoactive Substances Revenue (2020-2031)
- North America Psychoactive Substances Revenue by Type (2020-2031)
- North America Psychoactive Substances Revenue by Type (2020-2025)
- North America Psychoactive Substances Revenue by Type (2026-2031)
- North America Psychoactive Substances Revenue Share by Type (2020-2031)
- North America Psychoactive Substances Revenue by Application (2020-2031)
- North America Psychoactive Substances Revenue by Application (2020-2025)
- North America Psychoactive Substances Revenue by Application (2026-2031)
- North America Psychoactive Substances Revenue Share by Application (2020-2031)
- North America Psychoactive Substances Revenue by Country
- North America Psychoactive Substances Revenue by Country (2020 VS 2024 VS 2031)
- North America Psychoactive Substances Revenue by Country (2020-2025)
- North America Psychoactive Substances Revenue by Country (2026-2031)
- United States
- Canada
- Europe
- Europe Psychoactive Substances Revenue (2020-2031)
- Europe Psychoactive Substances Revenue by Type (2020-2031)
- Europe Psychoactive Substances Revenue by Type (2020-2025)
- Europe Psychoactive Substances Revenue by Type (2026-2031)
- Europe Psychoactive Substances Revenue Share by Type (2020-2031)
- Europe Psychoactive Substances Revenue by Application (2020-2031)
- Europe Psychoactive Substances Revenue by Application (2020-2025)
- Europe Psychoactive Substances Revenue by Application (2026-2031)
- Europe Psychoactive Substances Revenue Share by Application (2020-2031)
- Europe Psychoactive Substances Revenue by Country
- Europe Psychoactive Substances Revenue by Country (2020 VS 2024 VS 2031)
- Europe Psychoactive Substances Revenue by Country (2020-2025)
- Europe Psychoactive Substances Revenue by Country (2026-2031)
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- China
- China Psychoactive Substances Revenue (2020-2031)
- China Psychoactive Substances Revenue by Type (2020-2031)
- China Psychoactive Substances Revenue by Type (2020-2025)
- China Psychoactive Substances Revenue by Type (2026-2031)
- China Psychoactive Substances Revenue Share by Type (2020-2031)
- China Psychoactive Substances Revenue by Application (2020-2031)
- China Psychoactive Substances Revenue by Application (2020-2025)
- China Psychoactive Substances Revenue by Application (2026-2031)
- China Psychoactive Substances Revenue Share by Application (2020-2031)
- Asia (Excluding China)
- Asia Psychoactive Substances Revenue (2020-2031)
- Asia Psychoactive Substances Revenue by Type (2020-2031)
- Asia Psychoactive Substances Revenue by Type (2020-2025)
- Asia Psychoactive Substances Revenue by Type (2026-2031)
- Asia Psychoactive Substances Revenue Share by Type (2020-2031)
- Asia Psychoactive Substances Revenue by Application (2020-2031)
- Asia Psychoactive Substances Revenue by Application (2020-2025)
- Asia Psychoactive Substances Revenue by Application (2026-2031)
- Asia Psychoactive Substances Revenue Share by Application (2020-2031)
- Asia Psychoactive Substances Revenue by Country
- Asia Psychoactive Substances Revenue by Country (2020 VS 2024 VS 2031)
- Asia Psychoactive Substances Revenue by Country (2020-2025)
- Asia Psychoactive Substances Revenue by Country (2026-2031)
- Japan
- South Korea
- India
- Australia
- Taiwan
- Southeast Asia
- South America, Middle East and Africa
- SAMEA Psychoactive Substances Revenue (2020-2031)
- SAMEA Psychoactive Substances Revenue by Type (2020-2031)
- SAMEA Psychoactive Substances Revenue by Type (2020-2025)
- SAMEA Psychoactive Substances Revenue by Type (2026-2031)
- SAMEA Psychoactive Substances Revenue Share by Type (2020-2031)
- SAMEA Psychoactive Substances Revenue by Application (2020-2031)
- SAMEA Psychoactive Substances Revenue by Application (2020-2025)
- SAMEA Psychoactive Substances Revenue by Application (2026-2031)
- SAMEA Psychoactive Substances Revenue Share by Application (2020-2031)
- SAMEA Psychoactive Substances Revenue by Country
- SAMEA Psychoactive Substances Revenue by Country (2020 VS 2024 VS 2031)
- SAMEA Psychoactive Substances Revenue by Country (2020-2025)
- SAMEA Psychoactive Substances Revenue by Country (2026-2031)
- Brazil
- Argentina
- Chile
- Colombia
- Peru
- Saudi Arabia
- Israel
- UAE
- Turkey
- Iran
- Egypt
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
- Disclaimer
List of Tables
| Table 1 | :Global Psychoactive Substances Market Size Growth Rate by Type (US$ Million), 2020 VS 2024 VS 2031 |
| Table 2 | :Cannabinoids Major Player |
| Table 3 | :Hallucinogens Major Player |
| Table 4 | :Stimulants Major Player |
| Table 5 | :Depressants Major Player |
| Table 6 | :Global Psychoactive Substances Market Size Growth Rate by Application (US$ Million), 2020 VS 2024 VS 2031 |
| Table 7 | :Neuropathic Disorders Major Player |
| Table 8 | :Spasticity Major Player |
| Table 9 | :Cancer Major Player |
| Table 10 | :Psychoactive Substances Industry Trends |
| Table 11 | :Psychoactive Substances Industry Drivers |
| Table 12 | :Psychoactive Substances Industry Opportunities and Challenges |
| Table 13 | :Psychoactive Substances Industry Restraints |
| Table 14 | :Global Psychoactive Substances Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031 |
| Table 15 | :Global Psychoactive Substances Market Size by Region (2020-2025) & (US$ Million) |
| Table 16 | :Global Psychoactive Substances Market Share by Region (2020-2025) |
| Table 17 | :Global Psychoactive Substances Market Size by Region (2026-2031) & (US$ Million) |
| Table 18 | :Global Psychoactive Substances Market Share by Region (2026-2031) |
| Table 19 | :Global Psychoactive Substances Revenue by Players (US$ Million) & (2020-2025) |
| Table 20 | :Global Psychoactive Substances Revenue Market Share by Players (2020-2025) |
| Table 21 | :Global Psychoactive Substances Key Players Ranking, 2023 VS 2024 VS 2025 |
| Table 22 | :Global Psychoactive Substances Key Players Headquarters & Area Served |
| Table 23 | :Global Psychoactive Substances Players, Product Type & Application |
| Table 24 | :Global Psychoactive Substances Players Establishment Date |
| Table 25 | :Global Players Market Concentration Ratio (CR5 and HHI) |
| Table 26 | :Global Psychoactive Substances by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024) |
| Table 27 | :Global Psychoactive Substances Revenue by Type 2020 VS 2024 VS 2031 (US$ Million) |
| Table 28 | :Global Psychoactive Substances Revenue by Type (2020-2025) & (US$ Million) |
| Table 29 | :Global Psychoactive Substances Revenue by Type (2026-2031) & (US$ Million) |
| Table 30 | :Global Psychoactive Substances Revenue Market Share by Type (2020-2025) & (US$ Million) |
| Table 31 | :Global Psychoactive Substances Revenue Market Share by Type (2026-2031) & (US$ Million) |
| Table 32 | :Global Psychoactive Substances Revenue by Application 2020 VS 2024 VS 2031 (US$ Million) |
| Table 33 | :Global Psychoactive Substances Revenue by Application (2020-2025) & (US$ Million) |
| Table 34 | :Global Psychoactive Substances Revenue by Application (2026-2031) & (US$ Million) |
| Table 35 | :Global Psychoactive Substances Revenue Market Share by Application (2020-2025) & (US$ Million) |
| Table 36 | :Global Psychoactive Substances Revenue Market Share by Application (2026-2031) & (US$ Million) |
| Table 37 | :Alpha-CAT Company Information |
| Table 38 | :Alpha-CAT Business Overview |
| Table 39 | :Alpha-CAT Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 40 | :Alpha-CAT Psychoactive Substances Product Portfolio |
| Table 41 | :Alpha-CAT Recent Development |
| Table 42 | :AusCann Group Holdings Pty Ltd. Company Information |
| Table 43 | :AusCann Group Holdings Pty Ltd. Business Overview |
| Table 44 | :AusCann Group Holdings Pty Ltd. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 45 | :AusCann Group Holdings Pty Ltd. Psychoactive Substances Product Portfolio |
| Table 46 | :AusCann Group Holdings Pty Ltd. Recent Development |
| Table 47 | :Cannabics Pharmaceuticals Inc. Company Information |
| Table 48 | :Cannabics Pharmaceuticals Inc. Business Overview |
| Table 49 | :Cannabics Pharmaceuticals Inc. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 50 | :Cannabics Pharmaceuticals Inc. Psychoactive Substances Product Portfolio |
| Table 51 | :Cannabics Pharmaceuticals Inc. Recent Development |
| Table 52 | :Cape Bouvard Technologies Pty Ltd Company Information |
| Table 53 | :Cape Bouvard Technologies Pty Ltd Business Overview |
| Table 54 | :Cape Bouvard Technologies Pty Ltd Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 55 | :Cape Bouvard Technologies Pty Ltd Psychoactive Substances Product Portfolio |
| Table 56 | :Cape Bouvard Technologies Pty Ltd Recent Development |
| Table 57 | :Cyrelian Pty Ltd. Company Information |
| Table 58 | :Cyrelian Pty Ltd. Business Overview |
| Table 59 | :Cyrelian Pty Ltd. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 60 | :Cyrelian Pty Ltd. Psychoactive Substances Product Portfolio |
| Table 61 | :Cyrelian Pty Ltd. Recent Development |
| Table 62 | :Enecta. Company Information |
| Table 63 | :Enecta. Business Overview |
| Table 64 | :Enecta. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 65 | :Enecta. Psychoactive Substances Product Portfolio |
| Table 66 | :Enecta. Recent Development |
| Table 67 | :GD Pharma Company Information |
| Table 68 | :GD Pharma Business Overview |
| Table 69 | :GD Pharma Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 70 | :GD Pharma Psychoactive Substances Product Portfolio |
| Table 71 | :GD Pharma Recent Development |
| Table 72 | :GW Pharmaceuticals PLC. Company Information |
| Table 73 | :GW Pharmaceuticals PLC. Business Overview |
| Table 74 | :GW Pharmaceuticals PLC. Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 75 | :GW Pharmaceuticals PLC. Psychoactive Substances Product Portfolio |
| Table 76 | :GW Pharmaceuticals PLC. Recent Development |
| Table 77 | :MedReleaf Australia Company Information |
| Table 78 | :MedReleaf Australia Business Overview |
| Table 79 | :MedReleaf Australia Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 80 | :MedReleaf Australia Psychoactive Substances Product Portfolio |
| Table 81 | :MedReleaf Australia Recent Development |
| Table 82 | :Teewinot Life Sciences Company Information |
| Table 83 | :Teewinot Life Sciences Business Overview |
| Table 84 | :Teewinot Life Sciences Psychoactive Substances Revenue and Gross Margin (US$ Million) & (2020-2025) |
| Table 85 | :Teewinot Life Sciences Psychoactive Substances Product Portfolio |
| Table 86 | :Teewinot Life Sciences Recent Development |
| Table 87 | :Tilray Company Information |
| Table 88 | :Tilray Business Overview |
| Table 89 | :Tilray Psychoactive Substances Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
| Table 90 | :Tilray Psychoactive Substances Product Portfolio |
| Table 91 | :Tilray Recent Development |
| Table 92 | :Zynerba Pharmaceuticals Company Information |
| Table 93 | :Zynerba Pharmaceuticals Business Overview |
| Table 94 | :Zynerba Pharmaceuticals Psychoactive Substances Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025) |
| Table 95 | :Zynerba Pharmaceuticals Psychoactive Substances Product Portfolio |
| Table 96 | :Zynerba Pharmaceuticals Recent Development |
| Table 97 | :North America Psychoactive Substances Revenue by Type (2020-2025) & (US$ Million) |
| Table 98 | :North America Psychoactive Substances Revenue by Application (2020-2025) & (US$ Million) |
| Table 99 | :North America Psychoactive Substances Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
| Table 100 | :North America Psychoactive Substances Revenue by Country (2020-2025) & (US$ Million) |
| Table 101 | :North America Psychoactive Substances Revenue by Country (2026-2031) & (US$ Million) |
| Table 102 | :Europe Psychoactive Substances Revenue by Type (2020-2025) & (US$ Million) |
| Table 103 | :Europe Psychoactive Substances Revenue by Application (2020-2025) & (US$ Million) |
| Table 104 | :Europe Psychoactive Substances Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
| Table 105 | :Europe Psychoactive Substances Revenue by Country (2020-2025) & (US$ Million) |
| Table 106 | :Europe Psychoactive Substances Revenue by Country (2026-2031) & (US$ Million) |
| Table 107 | :China Psychoactive Substances Revenue by Type (2020-2025) & (US$ Million) |
| Table 108 | :China Psychoactive Substances Revenue by Application (2020-2025) & (US$ Million) |
| Table 109 | :Asia Psychoactive Substances Revenue by Type (2020-2025) & (US$ Million) |
| Table 110 | :Asia Psychoactive Substances Revenue by Application (2020-2025) & (US$ Million) |
| Table 111 | :Asia Psychoactive Substances Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
| Table 112 | :Asia Psychoactive Substances Revenue by Country (2020-2025) & (US$ Million) |
| Table 113 | :Asia Psychoactive Substances Revenue by Country (2026-2031) & (US$ Million) |
| Table 114 | :SAMEA Psychoactive Substances Revenue by Type (2020-2025) & (US$ Million) |
| Table 115 | :SAMEA Psychoactive Substances Revenue by Application (2020-2025) & (US$ Million) |
| Table 116 | :SAMEA Psychoactive Substances Revenue by Country (2020 VS 2024 VS 2031) & (US$ Million) |
| Table 117 | :SAMEA Psychoactive Substances Revenue by Country (2020-2025) & (US$ Million) |
| Table 118 | :SAMEA Psychoactive Substances Revenue by Country (2026-2031) & (US$ Million) |
| Table 119 | :Research Programs/Design for This Report |
| Table 120 | :Authors List of This Report |
| Table 121 | :Secondary Sources |
| Table 122 | :Primary Sources |
List of Figures
| Figure 1 | :Psychoactive Substances Image |
| Figure 2 | :Global Psychoactive Substances Market Size Growth Rate by Type (US$ Million), 2020 VS 2024 VS 2031 |
| Figure 3 | :Global Psychoactive Substances Market Size Share 2020 VS 2024 VS 2031 |
| Figure 4 | :Cannabinoids Image |
| Figure 5 | :Hallucinogens Image |
| Figure 6 | :Stimulants Image |
| Figure 7 | :Depressants Image |
| Figure 8 | :Global Psychoactive Substances Market Size Growth Rate by Application (US$ Million), 2020 VS 2024 VS 2031 |
| Figure 9 | :Global Psychoactive Substances Market Size Share 2020 VS 2024 VS 2031 |
| Figure 10 | :Neuropathic Disorders Image |
| Figure 11 | :Spasticity Image |
| Figure 12 | :Cancer Image |
| Figure 13 | :Global Psychoactive Substances Market Size (US$ Million) & (2020-2031) |
| Figure 14 | :Global Psychoactive Substances Market Size, (US$ Million), 2020 VS 2024 VS 2031 |
| Figure 15 | :Global Psychoactive Substances Market Share by Region: 2020 VS 2024 VS 2031 |
| Figure 16 | :Global Psychoactive Substances Players Revenue Share Top 10 and Top 5 in 2024 |
| Figure 17 | :Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
| Figure 18 | :Global Psychoactive Substances Revenue by Type (2020 VS 2024 VS 2031) & (US$ Million) |
| Figure 19 | :Global Psychoactive Substances Revenue Market Share 2020 VS 2024 VS 2031 |
| Figure 20 | :Global Psychoactive Substances Revenue Market Share by Type (2020-2031) |
| Figure 21 | :Global Psychoactive Substances Revenue by Application (2020 VS 2024 VS 2031) & (US$ Million) |
| Figure 22 | :Global Psychoactive Substances Revenue Market Share by Application (2020 VS 2024 VS 2031) |
| Figure 23 | :Global Psychoactive Substances Revenue Market Share by Application (2020-2031) |
| Figure 24 | :North America Psychoactive Substances Revenue YoY Growth (2020-2031) & (US$ Million) |
| Figure 25 | :North America Psychoactive Substances Revenue by Type (2026-2031) & (US$ Million) |
| Figure 26 | :North America Psychoactive Substances Revenue Share by Type (2020-2031) |
| Figure 27 | :North America Psychoactive Substances Revenue by Application (2026-2031) & (US$ Million) |
| Figure 28 | :North America Psychoactive Substances Revenue Share by Application (2020-2031) |
| Figure 29 | :North America Psychoactive Substances Revenue Share by Country (2020-2031) |
| Figure 30 | :United States Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 31 | :Canada Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 32 | :Mexico Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 33 | :Europe Psychoactive Substances Revenue YoY Growth (2020-2031) & (US$ Million) |
| Figure 34 | :Europe Psychoactive Substances Revenue by Type (2026-2031) & (US$ Million) |
| Figure 35 | :Europe Psychoactive Substances Revenue Share by Type (2020-2031) |
| Figure 36 | :Europe Psychoactive Substances Revenue by Application (2026-2031) & (US$ Million) |
| Figure 37 | :Europe Psychoactive Substances Revenue Share by Application (2020-2031) |
| Figure 38 | :Europe Psychoactive Substances Revenue Share by Country (2020-2031) |
| Figure 39 | :Germany Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 40 | :France Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 41 | :U.K. Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 42 | :Italy Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 43 | :Spain Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 44 | :Russia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 45 | :Netherlands Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 46 | :Nordic Countries Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 47 | :China Psychoactive Substances Revenue YoY Growth (2020-2031) & (US$ Million) |
| Figure 48 | :China Psychoactive Substances Revenue by Type (2026-2031) & (US$ Million) |
| Figure 49 | :China Psychoactive Substances Revenue Share by Type (2020-2031) |
| Figure 50 | :China Psychoactive Substances Revenue by Application (2026-2031) & (US$ Million) |
| Figure 51 | :China Psychoactive Substances Revenue Share by Application (2020-2031) |
| Figure 52 | :Asia Psychoactive Substances Revenue YoY Growth (2020-2031) & (US$ Million) |
| Figure 53 | :Asia Psychoactive Substances Revenue by Type (2026-2031) & (US$ Million) |
| Figure 54 | :Asia Psychoactive Substances Revenue Share by Type (2020-2031) |
| Figure 55 | :Asia Psychoactive Substances Revenue by Application (2026-2031) & (US$ Million) |
| Figure 56 | :Asia Psychoactive Substances Revenue Share by Application (2020-2031) |
| Figure 57 | :Asia Psychoactive Substances Revenue Share by Country (2020-2031) |
| Figure 58 | :Japan Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 59 | :South Korea Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 60 | :India Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 61 | :Australia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 62 | :Taiwan Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 63 | :Southeast Asia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 64 | :SAMEA Psychoactive Substances Revenue YoY Growth (2020-2031) & (US$ Million) |
| Figure 65 | :SAMEA Psychoactive Substances Revenue by Type (2026-2031) & (US$ Million) |
| Figure 66 | :SAMEA Psychoactive Substances Revenue Share by Type (2020-2031) |
| Figure 67 | :SAMEA Psychoactive Substances Revenue by Application (2026-2031) & (US$ Million) |
| Figure 68 | :SAMEA Psychoactive Substances Revenue Share by Application (2020-2031) |
| Figure 69 | :SAMEA Psychoactive Substances Revenue Share by Country (2020-2031) |
| Figure 70 | :Brazil Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 71 | :Argentina Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 72 | :Chile Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 73 | :Colombia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 74 | :Peru Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 75 | :Saudi Arabia Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 76 | :Israel Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 77 | :UAE Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 78 | :Turkey Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 79 | :Iran Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 80 | :Egypt Psychoactive Substances Revenue YoY Growth (US$ Million) & (2020-2031) |
| Figure 81 | :Years Considered |
| Figure 82 | :Research Process |
| Figure 83 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global Psychoactive Substances Market Analysis and Forecast 2025-2031
Pages: 193
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.